多重工程T细胞疫苗促进TCR-T细胞疗法增强抗瘤功能,并消除异质固体瘤
Xuan Che1, Shen Zheng1, Yuan Sun1
1Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing 100191, China.
概括
一种新型的多重工程T细胞疫苗 (Multi-Tvac) 增强了T细胞受体 (TCR) -T细胞治疗固体瘤的功能. 这种方法克服了抗原损失并改善了T细胞的持久性,从而导致模型中瘤的完全排斥.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞工程 细胞工程
背景情况:
- 用T细胞受体 (TCR) 进行的T细胞疗法对固体瘤有望,但面临着抗原损失和T细胞持久性差等挑战.
- 目前的TCR-T细胞疗法经常与瘤异质性和免疫逃避作斗争,限制了临床疗效.
研究的目的:
- 开发和评估一种多工程T细胞疫苗 (Multi-Tvac),以加强TCR-T细胞治疗抗原异质固体瘤.
- 调查Multi-Tvac在增强T细胞抗瘤功能,改善持久性和克服瘤脱离中的机制.
主要方法:
- 开发了多Tvac,包括TCR向,瘤新抗原和LAG-3Ig辅助剂.
- 在固体瘤模型中与TCR-T细胞疗法结合使用Multi-Tvac,包括抗原异质设置.
- 评估T细胞功能,持久性,瘤反应和免疫细胞激活,包括树突细胞成熟和二级淋巴体器官中的抗原呈现.
主要成果:
- 多Tvac显著增强树突细胞成熟和TCR-T细胞抗瘤活性,同时减少T细胞耗尽.
- 与Multi-Tvac联合治疗诱导了对TCR-T细胞单一疗法耐药的固体瘤的持久反应.
- 多种Tvac预防了抗原损失瘤逃逸,并在抗原异质固体瘤模型中实现了完整的反应.
结论:
- 多Tvac作为一个强大的治疗性疫苗接种平台,使TCR-T细胞能够克服固体瘤治疗的主要临床障碍.
- 这种多重工程疫苗策略增强了抗原呈现,并协调了内源性免疫反应,这对于持续的抗瘤疗效至关重要.
- 这种方法代表了超越简单的TCR定向杀伤的重大进步,为治疗具有挑战性的固体瘤提供了一种新的策略.
相关概念视频
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
01:30Cancer Vaccines
347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:27Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861